Nanomedicines for Breast Cancer Theranostics Micro and Nano Technologies Series
Coordonnateurs : Thorat Nanasaheb D., Bauer Joanna
Nanomedicines for Breast Cancer Theranostics addresses the translational aspects and clinical perspectives of breast cancer nanomedicine from a multidisciplinary perspective. The book summarizes research efforts at the preclinical and clinical stage of nanostructures and nanomedicine for dealing with the important challenge of nanomedicine translation in breast cancer theranostics. This book is an important resource for those working in both academia and industry, focusing on hot topics in biomaterials, biomedical engineering, drug delivery and oncology.
1. Nanomedicine: next generation modality of breast cancer therapeutics 2. Physical and Chemical properties of nanostructures 3. Biological Perspectives of Hybrid nanostructures 4. Novel hybrid nanostructures in breast cancer nanomedicine 5. Synergy between nanoparticles and breast cancer theranostics 6. Remotely stimulated Nano medicine for breast cancer therapy 7. Functional Nanostructures for drug resistant breast cancer theranostics 8. Nanomedicine for early diagnosis of breast cancer 9. Nanomedicine strategies for chemoresistant breast cancer theranostics 10. Cellular Interaction and Toxicity of Nanostructures 11. Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship 12. A New Approach for Cancer Treatment: from Specific Induction of Breast Cancer to Innovative Gold-Nanoparticle Mediated Thermal Therapies 13. Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine 14. Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer 15. Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines 16. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine
Materials Scientists; Engineers; Oncologists; Pharmaceutical Scientists; Biomedical Researchers
Dr. Nanasaheb Thorat is Principal Investigator funded by the Science Foundation Ireland (SFI) and Irish Research Council (IRC) Pathway Program at the University of Limerick, Ireland. He is also a Marie Curie Visiting Research Scientist at the University of Oxford, UK.
He has been deeply engaged in collaborative work with the many eminent scientists from Japan, USA, Germany, Korea, Ireland, India, Poland, Saudi Arabia and Australia. Dr. Thorat has received the European Commission’s innovation Radar “Grand Prix of the Innovation Radar Prize 2020 for developing ground-breaking technology for breast cancer theranostics.Joanna Bauer is Assistant Professor at the Department of Biomedical Engineering at the Wroclaw University of Science and Technology, Poland. Her research focuses on multidisciplinary biomedical engineering projects related to personalized and preventive medicine, nano-biomaterials synthesis, characterization and functionalization, biomedical optics using visible and infrared.imaging, as well as image analysis and pattern recognition.
- Shows how the discovery of new nanomedicines is leading directly to an increase in the early-stage diagnosis of breast cancer
- Includes coverage of breast cancer nanomedicine standardization and characterization, highlighting newly developed treatments, diagnostics and treatment monitoring tools
- Explains why the design of nanobiomaterials make them effective drug carriers when treating breast cancer
Date de parution : 03-2020
Ouvrage de 438 p.
19x23.3 cm
Thèmes de Nanomedicines for Breast Cancer Theranostics :
Mots-clés :
Antibody-drug conjugates; Anticancer drugs; Breast cancer (BC); Cancer nanomedicine; Carrier; Cell biology; Cellular interaction; Characteristics of tumor models; Chemical properties; Chemotherapy (CHT); Clinical trials; CNT; Combined nanotherapeutics; Computed tomography (CT); Conventional therapy; Drug; Experimental models; Fluorescence imaging (FI); Gold nanoparticles; Gold NPs; Harmfulness of nanoparticles; Hybrid nanoparticles; Hybrid nanostructures; Hyperthermia; In vitro models; Iron oxide nanoparticles; Liposomes; Magnetic hyperthermia therapy (MHT); Magnetic properties; Magnetic resonance imaging (MRI); Mechanical properties; Mesoporous; Micelles; Mouse models; MRI; Multidrug resistance; Nanomaterials; Nanomedicine; Nanoparticle; Nanoparticles; Nanotechnology; Nanotheranostics; Oncology models for nanoparticles; Optical properties; Pharmacodynamics; Pharmacokinetics; Photodynamic/photothermal therapy (PDT/PTT); Photothermal therapy; Physical properties; Physicochemical properties; Preclinical animal models; Quantum dots; Radiation release; Regulatory; Remotely triggered nanomedicine; Selection criteria; Smart therapeutic systems; SPIONPs; Targeted drug delivery; Theranostics; Therapy; Toxicity; Triggered
